Targeted chemo-photodynamic therapy toward esophageal cancer by GSH-sensitive theranostic nanoplatform

• DOI: 10.1016/j.biopha.2022.113506
• Publication Date: 2022-08-08T05:53:36Z
• Authors: Guodong Ren; ZiCheng Wang; Yafei Tian; Jinyao Li; Yingyu Ma; Liang Zhou; Chengwu Zhang; Lixia Guo; Haipeng Diao; Lihong Li; Li Lu; Sufang Ma; Zhifang Wu; Lili Yan; Wen Liu
• Keywords: 0301 basic medicine; Photosensitizing Agents; Porphyrins; Epidermal Growth Factor; Esophageal Neoplasms; Glutathione; Theranostic Nanomedicine; 3. Good health; 03 medical and health sciences; Photochemotherapy; Cell Line, Tumor; Tumor Microenvironment; Humans; Nanoparticles; Precision Medicine

As the sixth leading cause of cancer death, esophageal cancer is threatening the life of people worldwide. Traditional treatments, such as surgery, chemotherapy, radiotherapy, are facing always augmented challenges including invasion, multidrug resistance (MDR), off-target toxicity. Chemo & Photodynamic synergistic therapy represents one promising strategy for improved treatment efficiency. But it is still hindered by the lack of tumor targeting, deleterious side effects, and unfavorable microenvironment for photodynamic therapy (PDT). To overcome those obstacles, one theranostic nano-assambly drug, GCDs-Ce6/Pt-EGF, was designed and fabricated. Green fluorescence carbon dots (GCDs) with the excellent optical properties, modifiability and low toxicity were prepared as drug carrier. Epidermal growth factor (EGF) was conjugated to the nano-assembly to realize tumor specific targeting. Chlorin e6 (Ce6) in the presence of laser irradiation achieved PDT by generating proapoptosis reactive oxygen species (ROS). Moreover, Ce6 incorporated into GCDs endowed the nano-assambly imaging ability and facilitate image-guided therapy. Pt(IV), cisplatin prodrug, in the nano-assambly depleted the glutathione (GSH) of tumor microenvironment when it was reduced to cytotoxicity Pt(II). Compared with single treatment, GCDs-Ce6/Pt-EGF exhibited enhanced tumor cell killing capacity and better biosafety in vitro and in vivo, especially for EGFR bearing tumor. It paved ways for developing novel theranostic agent to be potentially applied in clinic.